Relationship between uric acid and kidney function in adults at risk for tumor lysis syndrome.

Uric acid acute kidney injury lymphoma and Hodgkin disease rasburicase tumor lysis syndrome

Journal

Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422

Informations de publication

Date de publication:
12 2021
Historique:
pubmed: 26 6 2021
medline: 15 4 2022
entrez: 25 6 2021
Statut: ppublish

Résumé

Uric acid drives acute kidney injury in tumor lysis syndrome (TLS). This study investigated the relationship between uric acid and changes in estimated glomerular filtration rate (eGFR) in adults at risk for TLS. Linear regression was used to evaluate the relationship between uric acid area under the curve (AUC) and percent change in eGFR from baseline at hospital dismissal, 1 and 3 months. In 210 included participants, each 100 mg*hour/dL increase in 24 h AUC was associated with an average decline in eGFR at hospital dismissal of 9% (95%CI 3, 15) in univariate analysis. Each 100 mg*hour/dL increase in 24 h AUC was independently associated with an average decline in eGFR of 8% (95%CI 2, 13) at 1 month after dismissal. Additional research is needed to confirm these findings and determine whether treatments that reduce overall uric acid exposure improve kidney outcomes. Preserving kidney health could favorably impact cancer treatment eligibility, tolerability, and outcomes.

Identifiants

pubmed: 34169786
doi: 10.1080/10428194.2021.1941931
pmc: PMC8639629
mid: NIHMS1741691
doi:

Substances chimiques

Uric Acid 268B43MJ25
Urate Oxidase EC 1.7.3.3

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3152-3159

Subventions

Organisme : NIAID NIH HHS
ID : K23 AI143882
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG034676
Pays : United States
Organisme : NIA NIH HHS
ID : R33 AG058738
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002377
Pays : United States

Commentaires et corrections

Type : CommentIn

Références

Leuk Lymphoma. 2019 Sep;60(9):2271-2277
pubmed: 31223041
Am J Kidney Dis. 2015 Apr;65(4):543-9
pubmed: 25595565
J Am Soc Nephrol. 2020 Dec;31(12):2773-2792
pubmed: 32938648
J Nephrol. 2020 Aug;33(4):715-724
pubmed: 31933161
J Nephrol. 2021 Mar 23;:
pubmed: 33755930
PLoS One. 2013;8(2):e55870
pubmed: 23457485
Clin Lymphoma Myeloma Leuk. 2017 Mar;17(3):173-178
pubmed: 27965022
Contrib Nephrol. 2018;192:48-55
pubmed: 29393109
PLoS One. 2015 Mar 16;10(3):e0119497
pubmed: 25775138
Nutr Metab Cardiovasc Dis. 2020 Nov 27;30(12):2343-2350
pubmed: 32912790
J Clin Oncol. 2008 Jun 1;26(16):2767-78
pubmed: 18509186
Br J Haematol. 2013 Aug;162(4):489-97
pubmed: 23772757
Oncologist. 2017 Dec;22(12):1506-1509
pubmed: 28904174
Nephron. 2016;134(4):231-237
pubmed: 27548821
Expert Opin Pharmacother. 2009 Apr;10(5):737-42
pubmed: 19351224
Am J Epidemiol. 2011 May 1;173(9):1059-68
pubmed: 21430193
Ann Intern Med. 1999 Mar 16;130(6):461-70
pubmed: 10075613
Nephrol Dial Transplant. 2014 Feb;29(2):406-13
pubmed: 24042021
Nephrol Dial Transplant. 2009 Oct;24(10):2960-4
pubmed: 19581334
Nephrology (Carlton). 2017 Jan;22(1):85-88
pubmed: 27119419
Crit Care. 2013 Oct 22;17(5):R250
pubmed: 24148658
Mayo Clin Proc. 2012 Feb;87(2):151-60
pubmed: 22305027
Clin Lymphoma Myeloma. 2008 Feb;8(1):44-51
pubmed: 18501087
Clin J Am Soc Nephrol. 2014 Jun 6;9(6):1007-14
pubmed: 24677557
N Engl J Med. 2020 Jun 25;382(26):2504-2513
pubmed: 32579811
Haematologica. 2008 Jan;93(1):67-74
pubmed: 18166787
N Engl J Med. 2020 Jun 25;382(26):2493-2503
pubmed: 32579810
Nat Rev Nephrol. 2017 Apr;13(4):241-257
pubmed: 28239173
N Engl J Med. 2018 Feb 1;378(5):449-459
pubmed: 29385376
Blood. 2001 May 15;97(10):2998-3003
pubmed: 11342423
Am J Kidney Dis. 2014 Oct;64(4):550-7
pubmed: 24906981
Leuk Lymphoma. 2003 Jan;44(1):77-83
pubmed: 12691145
Intensive Care Med. 2016 Feb;42(2):137-46
pubmed: 26626062
J Clin Oncol. 2010 Sep 20;28(27):4207-13
pubmed: 20713865
J Clin Oncol. 2021 May 20;39(15):1641-1649
pubmed: 33529046
Am J Kidney Dis. 2018 Dec;72(6):798-810
pubmed: 30177485

Auteurs

Heather P May (HP)

Department of Pharmacy, Mayo Clinic, Rochester, MN, USA.

Kristin C Mara (KC)

Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.

Erin F Barreto (EF)

Department of Pharmacy, Mayo Clinic, Rochester, MN, USA.
Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery.

Nelson Leung (N)

Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Division of Nephrology and Hypertension and Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.

Thomas M Habermann (TM)

Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH